Loading
CHRYSALIS was the first human study of amivantamab, an antibody that grabs both EGFR and MET; its cohort of people with EGFR exon 20 insertion lung cancer responded well enough to earn the drug its first approval.
CHRYSALIS is the phase 1 dose-escalation and expansion study of amivantamab, a bispecific antibody against EGFR and MET, in advanced non-small-cell lung cancer. Expansion cohorts tested the antibody alone in EGFR exon 20 insertion disease after platinum chemotherapy, and in combination with the third-generation EGFR inhibitor lazertinib or with chemotherapy in other EGFR-mutant settings.
The exon 20 insertion cohort, a group for which conventional EGFR inhibitors work poorly, showed a clinically meaningful response rate with durable responses, and amivantamab received accelerated approval in the United States in May 2021 for that indication. The combination cohorts with lazertinib provided the rationale for the phase 3 MARIPOSA and MARIPOSA-2 trials.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
751 enrolled.
95% CI 29 to 51
SourceShares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
Shares Johnson & Johnson and the tag subtype-trials.
Shares Johnson & Johnson and the tag subtype-trials.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
Shares Johnson & Johnson and the tag subtype-trials.
Shares Johnson & Johnson and the tag subtype-trials.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.